The early rebound in serum HCV RNA during HCV dynamic studies with high-dose interferon may be due to de novo infection with interferon escape quasispecies.
We simultaneously measured serum alanine aminotransferase (ALT) and HCV RNA at rapid intervals in chronic HCV liver disease patients during interferon therapy alone or in combination with ribavirin and amantadine.
Parameters t0, rv was computed as V0 £ c, defined in equation -- is determined by ANR D interferon monotherapy patients without rebound.

http://www.biokin.com/papers/Baka0326.pdf
HCV RNA viral dynamic data observed during phase 1 (0--48 hr) for monotherapy patients and patients treated with interferon and ribavirin are shown graphically in Figure 1a, b. patients, Digestive Diseases.

Ribavirin_hepatitis%20C.PDF

Hepatitis C virus (HCV) is the most common cause of parenterally acquired hepatitis in the developed world.
Extended courses of interferon therapy yield only modest improvements in response and are poorly tolerated.
In group A (ribavirin alone), ALT levels were normalised during treatment in some HCV-1b and HCV-2a patients only.
In a second trial, 60 non-cirrhotic patients with HCV were randomised to receive either ribavirin plus interferon alfa, interferon alfa alone, or no treatment for 24 weeks.

http://www.nyrdtc.nhs.uk/docs/eva/Ribavirin_hepatitis%20C.PDF
Current evidence suggests that treatment of chronic hepatitis C with interferon alfa in combination with ribavirin for 6 months compared to interferon alfa monotherapy increases the short term biological response rate from about 40%-50% to 60%-76% and the virological response rate from 40%-50% to around 60%. interferon alfa, HCV.

Ribavirin_InfosheetE.pdf

Ribavirin is an anti-viral medication that can be delivered as an aerosol, or suspension of small particles in air.
Engineering controls, work practices, and personal protective equipment are used to prevent exposure to employees and visitors at Duke.
Duke policy requires that, when possible, assignments be made so pregnant* employees are not required to enter patient rooms during Ribavirin therapy.
If this occurs, all employees must wear fit-tested N-95 respirators or loose-fitting Powered Air-Purifying Respirators (PAPRs) when they enter a patient room during Ribavirin treatment.

Persons with contact lenses should wear tight-fitting goggles or other eye protection if they will be in the room for a prolonged period of time. Ribavirin, Duke.

info_c.pdf

Hepatitis C is a liver disease caused by infection with hepatitis C virus (HCV).
An estimated 2.7 million Americans are chronically infected, with many showing no signs or symptoms and unaware of their infection.
Less than 3% of persons die as a result of their chronic HCV liver disease; however, HCV-related chronic liver disease remains the leading cause of liver transplantation.
Among injection drug users, up to 90% are infected within the first 12 months of their first injection without symptoms for 10--30 years.
There is a 1.8% risk of acquiring HCV after a needlestick contaminated with HCV-positive blood.

http://www.hepfi.org/pdfs/info_c.pdf
Hepatitis C infected person should be evaluated for possible treatment with antiviral drugs by a physician knowledgeable about hepatitis C. Chronic infection occurs in 55%-85% of infected persons, and chronic liver disease develops in 70% of those who are chronically infected. infection, virus.